FDA May Pull Pfizer COVID Shot for Kids Under 5

Industry Insights from Next Move Strategy Consulting

In a potential shift to U.S. immunization policy, the Food and Drug Administration (FDA) is evaluating whether to withdraw its authorization for Pfizer’s COVID-19 vaccines in healthy children under the age of 5, the company confirmed to CNBC. If enacted, the move could leave most children in this age group without an available vaccine option, as alternatives remain limited to narrower populations.

A Significant Policy Adjustment in Pediatric COVID Immunization

The decision under consideration would primarily affect healthy children aged 6 months to 4 years, who currently have access to Pfizer’s shot under an emergency use authorization. Moderna’s vaccine remains available only to children with at least one underlying condition that raises their risk of severe illness. Novavax’s protein-based shot has never been authorized for children under 12.

The FDA informed Pfizer it may not renew the long-standing emergency use authorization for the upcoming fall and winter season. In response, Pfizer has requested the authorization remain in place and confirmed ongoing discussions with the agency. The company emphasized that the deliberations are not linked to the vaccine’s safety or efficacy, which it maintains has a favorable profile.

Broader Context and Leadership Influence

The potential withdrawal follows a series of recent U.S. health agency actions that have altered or reduced vaccine recommendations since Health and Human Services Secretary Robert F. Kennedy Jr., a known vaccine skeptic, assumed leadership. Kennedy has previously petitioned the FDA to revoke mRNA vaccine authorizations and, earlier this year, announced that the Centers for Disease Control and Prevention (CDC) removed its recommendation for COVID vaccines for healthy children and pregnant women. 

Current Landscape of Pediatric Vaccine Availability

Should the FDA proceed, healthy children under 5 would be left without an authorized COVID-19 vaccine. While COVID-19 generally causes mild illness in most children, higher risks remain for infants under 1 and those with specific medical conditions.

The Guardian first reported on the FDA’s potential decision. The outcome of the agency’s review could redefine vaccine access for one of the youngest and most vulnerable age groups heading into respiratory virus season.

Source: CNBC

Prepared by: Next Move Strategy Consulting